Third International Symposium on Sigma-2 Receptors

The following video archives are available from:

The Third International Symposium on Sigma-2 Receptors:
Role in Health and Disease

November 3, 2018

Symposium Booklet:
Introductory statement
Agenda
Speaker biographies
Symposium 
Handout

Videos of individual speakers may be viewed below:

Introduction to Session and Speakers

Susan Catalano, Ph.D.
Chief Science Officer and Founder, Cognition Therapeutics, Inc.

Biography of Dr. Catalano
Play Video
Differential Sigma-2 Receptor/TMEM97-Mediated Cytotoxic and Metabolic Stimulative Properties of Monovalent and Bivalent SN79 Analogs
Wayne D. Bowen, Ph.D.
Upjohn Professor of Pharmacology, Professor of Biology, Chair of the Department of Molecular Pharmacology, Physiology & Biotechnology,
Brown University
Biography of Dr. Bowen
Targeting Sigma-2 Receptor (σ2R)/TMEM97 to Address Unmet Medical Needs in Neuroscience
Stephen F. Martin, Ph.D.
M. June and J. Virgil Waggoner Regents Chair in Chemistry
University of Texas at Austin
Biography of Dr. Martin
Play Video
Sigma 2 Receptor-Interacting Protein PGRMC1 is Descended from the Hopanoid Synthetic Pathway of the Endosymbiotic Proto-Mitochondrion
Michael A. Cahill, Ph.D.
Lecturer in Biochemistry and Cell Biology
Charles Sturt University, New South Wales, Australia
Biography of Dr. Cahill
Let7i as a Key Regulator of PGRMC1 and Progesterone-Induced Neuroprotection
Meharvan “Sonny” Singh, Ph.D.
Professor, Department of Pharmacology and Neuroscience, Interim Executive Director, Institute for Healthy Aging
University of North Texas Health Science Center
Biography of Dr. Singh
Clinical Evidence of Synaptic Protection in Alzheimer’s Patients following Treatment of CT1812
Susan Catalano, Ph.D.
Chief Science Officer and Founder
Cognition Therapeutics, Inc.
Biography of Dr. Catalano
Sigma-2 Antagonist CT1812 Protects Synapses from Abeta Oligomer-Induced Loss, In Vitro
Nicholas J. Izzo, Ph.D.
Principal Scientist and Director of Screening
Cognition Therapeutics, Inc.

Biography of
Dr. Izzo

KEYNOTE ADDRESS: APOE4 Associated Changes in the Synaptic Proteome in Human Alzheimer’s Disease Brain
Tara Spires-Jones, DPhil
Professor of Neurodegeneration at the UK Dementia Research Institute Programme, Lead Deputy Director of the Centre for Discovery Brain Sciences
University of Edinburgh, Scotland

Biography of
Dr. Spires-Jones

The Essential Role of Sigma-2 Receptor/TMEM97 and Progesterone Receptor Membrane Component 1 in the Internalization of Low-Density Lipoprotein via and Interaction with the Low-Density Lipoprotein Receptor
Aladdin A. Riad, Ph.D.
Postdoctoral Fellow
University of Pennsylvania

Biography of
Dr. Riad

A Novel Mechanism Underlying Synaptic Plasticity: Roles for PGRMC1 and TMEM97?
Timothy E. Kennedy, Ph.D.
co-Director, McGill Program in Neuroengineering; Professor, Department of Neurology and Neurosurgery; Professor, Department of Anatomy and Cell Biology
Montreal Neurological Institute
McGill University, Montreal, Quebec, Canada

Biography of
Dr. Kennedy

Biological Roles of TMEM97 and PGRMC1 in Cell Growth and Sigma-2 Ligand-Induced Cell Death
Chenbo Zeng, Ph.D.
Research Assistant Professor of Radiology
University of Pennsylvania

Biography of
Dr. Zeng

Identification of a Second [3H]DTG Binding Site on TMEM97-KO Cell Membranes
Robert H. Mach, Ph.D.
Britton Chance Professor of Radiology
University of Pennsylvania

Biography of
Dr. Mach

Scroll to Top

Thank you for your interest in Cognition’s publications. A PDF of the poster you are interested in will be made available in accordance with the congress’ embargo policy. Please check back soon. 

You are now leaving the Cognition Therapeutics website

Cognition Therapeutics assumes no responsibility for the content of third-party website. Neither does Cognition control, endorse or guarantee any aspect of your use of third-party sites. We encourage you to read and evaluate terms of use, privacy and other policies of the destination site as they may differ from Cognition’s policies.

You are now leaving the Cognition Therapeutics website

Cognition Therapeutics assumes no responsibility for the content of third-party website. Neither does Cognition control, endorse or guarantee any aspect of your use of third-party sites. We encourage you to read and evaluate terms of use, privacy and other policies of the destination site as they may differ from Cognition’s policies.

You are now leaving the Cognition Therapeutics website

Cognition Therapeutics assumes no responsibility for the content of third-party website. Neither does Cognition control, endorse or guarantee any aspect of your use of third-party sites. We encourage you to read and evaluate terms of use, privacy and other policies of the destination site as they may differ from Cognition’s policies.

You are now leaving the Cognition Therapeutics website

Cognition Therapeutics assumes no responsibility for the content of third-party website. Neither does Cognition control, endorse or guarantee any aspect of your use of third-party sites. We encourage you to read and evaluate terms of use, privacy and other policies of the destination site as they may differ from Cognition’s policies.

You are now leaving the Cognition Therapeutics website

Cognition Therapeutics assumes no responsibility for the content of third-party website. Neither does Cognition control, endorse or guarantee any aspect of your use of third-party sites. We encourage you to read and evaluate terms of use, privacy and other policies of the destination site as they may differ from Cognition’s policies.